Adimlecleucel

N/A

Report date: 2022/11/20 14:41:33

Base Information

Drug NameAdimlecleucel
Drug Alias NameCMV-peptide-specific T-cells - Atara/MSKCCCytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer CenterCytomegalovirus virus specific cytotoxic T-lymphocytes - Atara/MSKCCCytomegalovirus-pp65-specific-cytotoxic-T-lymphocytes-Atara/MSKCCCMV targeted T-cell therapy - Atara/MSKCC +[9] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsViremiaCytomegalovirus InfectionsHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterAtara Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesAtara Biotherapeutics IncDuke University
Active IndicationsViremiaCytomegalovirus Infections
Inactive IndicationsHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksN/A